On the 3rd, Celltrion disclosed the interim results based on the 24th week of the global phase 3 clinical trial of CT-P42, an eye disease treatment Eylea biosimilar. Celltrion is conducting clinical trials for 52 weeks on 348 DME patients in 13 countries, including Germany and Spain. The interim results released this time are the results of clinical progress up to 24 weeks. Celltrion is conducting clinical trials by dividing it into two groups: the CT-P42 administration group and the original drug administration group. The primary endpoint is the change in BCVA value measured at week 8 from baseline. As a result of the measurement, CT-P42 satisfied the predefined equivalence criteria. Secondary evaluation indicators,